Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma

Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma

ABSTRACT Introduction This study aimed to compare the long‐term effects of neoadjuvant therapy and upfront surgery on overall survival (OS) and progression‐free survival (PFS) in patients with resectable pancreatic ductal adenocarcinoma (PDAC). Methods We retrospectively analyzed 202 patients, inclu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer medicine (Malden, MA) MA), 2024-11, Vol.13 (22), p.e70363-n/a
Hauptverfasser: Shin, Kyung In, Yoon, Min Sung, Kim, Jee Hoon, Jang, Won Joon, Leem, Galam, Jo, Jung Hyun, Chung, Moon Jae, Park, Jeong Youp, Park, Seung Woo, Hwang, Ho Kyoung, Kang, Chang Moo, Kim, Seung‐seob, Park, Mi‐Suk, Lee, Hee Seung, Bang, Seungmin
Format: Artikel
Sprache:eng
Schlagworte:
Adenocarcinoma
Aged
Cancer therapies
Carcinoma, Pancreatic Ductal - mortality
Carcinoma, Pancreatic Ductal - pathology
Carcinoma, Pancreatic Ductal - surgery
Carcinoma, Pancreatic Ductal - therapy
Chemotherapy
Electronic health records
Female
Hospitals
Humans
long‐term results
Male
Medical records
Middle Aged
neoadjuvant therapy
Neoadjuvant Therapy - methods
overall survival
Pancreas
Pancreatectomy
Pancreatic cancer
pancreatic neoplasm
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - surgery
Pancreatic Neoplasms - therapy
Patients
progression‐free survival
Propensity Score
Retrospective Studies
Software
Surgery
Surgical outcomes
Survival
Survival analysis
Survival Rate
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Introduction This study aimed to compare the long‐term effects of neoadjuvant therapy and upfront surgery on overall survival (OS) and progression‐free survival (PFS) in patients with resectable pancreatic ductal adenocarcinoma (PDAC). Methods We retrospectively analyzed 202 patients, including 167 who had upfront surgery and 35 who received neoadjuvant therapy followed by surgery. Surgical outcomes and survival rates were compared using propensity score matching to minimize selection bias. Results Neoadjuvant therapy showed significantly longer 75% OS (72.7 months vs. 28.3 months, p = 0.032) and PFS (29.6 months vs. 13.2 months, p 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.70363